cimb-logo

Journal Browser

Journal Browser

New Insight: Enzymes as Targets for Drug Development, 2nd Edition

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Biochemistry, Molecular and Cellular Biology".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 486

Special Issue Editor

Special Issue Information

Dear Colleagues,

In the pharmaceutical community, the most attractive targets for drug development are enzymes. The characterization of enzymes is critical in understanding their reactions. Many analytical methods are needed to completely characterize them, such as purification; kinetics; protein stabilization; optimal pH conditions; temperature; ionic strength; subtract or product binding; ligand/inhibitor/protein interactions; three-dimensional structure; and conformational changes. Recently, in silico analysis has been successfully used for enzyme characterization. Molecular docking and molecular dynamics should are also major techniques. This Special Issue brings together a large number of intriguing subjects to promote ideas on enzymes as targets for drug development.

The following topics will be included in this Special Issue:

  • The improvement of enzyme purification;
  • The development of novel inhibitors;
  • The investigation of enzyme mechanism;
  • Understanding enzyme conformation changes.

Prof. Dr. Sung-Kun (Sean) Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • enzyme kinetics
  • enzyme–ligand or protein-protein interactions
  • enzyme inhibitions
  • enzyme purifications and optimal conditions
  • enzyme or protein structures
  • enzyme or protein computational analysis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2823 KiB  
Article
Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis
by Jessica Schüler, Martina Vockerodt, Niloofar Salehzadeh, Jürgen Becker and Jörg Wilting
Curr. Issues Mol. Biol. 2024, 46(7), 7395-7410; https://doi.org/10.3390/cimb46070439 (registering DOI) - 13 Jul 2024
Viewed by 190
Abstract
Cholangiocellular carcinoma (CCA) is the second most common primary liver cancer, with increasing incidence worldwide and inadequate therapeutic options. Intra- and extrahepatic bile ducts have distinctly different embryonic origins and developmental behavior, and accordingly, intra- and extrahepatic CCAs (ICC vs. ECC) are molecularly [...] Read more.
Cholangiocellular carcinoma (CCA) is the second most common primary liver cancer, with increasing incidence worldwide and inadequate therapeutic options. Intra- and extrahepatic bile ducts have distinctly different embryonic origins and developmental behavior, and accordingly, intra- and extrahepatic CCAs (ICC vs. ECC) are molecularly different. A promising strategy in oncotherapy is targeted therapy, targeting proteins that regulate cell survival and proliferation, such as the MAPK/ERK and PI3K/AKT/mTOR signaling pathways. Inhibitors of these pathways have been tested previously in CCA cell lines. However, these cell lines could not be clearly assigned to ICC or ECC, and the results indicated apoptosis induction by targeted therapeutics. We tested targeted therapeutics (selumetinib, MK2206) in three defined ICC cell lines (HuH28, RBE, SSP25). We observed additive effects of the dual inhibition of the two pathways, in accordance with the inhibition of phospho-AKT and phospho-ERK1/2 expression. Proliferation was blocked more effectively with dual inhibition than with each single inhibition, but cell numbers did not drop below baseline. Accordingly, we observed G1 phase arrest but not apoptosis or cell death (measured by cleaved caspase-3, AIFM1 regulation, sub-G0/G1 phase). We conclude that the dual inhibition of the MAPK/ERK and PI3K/AKT/mTOR pathways is highly effective to block the proliferation of ICC cell lines in vitro; however, potential clinical applications must be critically examined, as a proliferation block could also induce resistance to standard therapies. Full article
(This article belongs to the Special Issue New Insight: Enzymes as Targets for Drug Development, 2nd Edition)
Back to TopTop